About The Study: This study found that comparable levels of sensitivity and specificity as reported for the multitarget stool RNA (mt-sRNA) test in the colorectal cancer (CRC)-PREVENT study could be achieved by lowering the fecal immunochemical test positivity threshold, without additional mt-sRNA testing. The findings are similar to previous observations for multitarget stool DNA testing.
Corresponding Author: To contact the corresponding author, Hermann Brenner, M.D., M.P.H., email h.brenner@dkfz.de.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.9289)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.9289?guestAccessKey=e9d1d41d-b503-4d1c-8d00-6d5666d0c76f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060124
Journal
JAMA